Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article describes telogen effluvium as diffuse cyclic hair loss in women caused by systemic stresses, diseases, or physiological situations, but reports no new clinical results.

In this study, researchers observed that phospholipid-calcium carbonate hybrid nanoparticles effectively delivered Tofacitinib citrate topically, which significantly inhibited hair follicle apoptosis and promoted hair growth in a mouse model of chemotherapy-induced alopecia, compared to a traditional Tofacitinib solution.

This study suggests that observing the acute telogen effluvium triad—frontal fringe, temporal recess, and occipital fringe—can aid in diagnosing telogen effluvium during resolution phases, despite challenges like negative pull tests.

This study concluded that oral tofacitinib significantly improved hair growth in patients with alopecia areata, alopecia totalis, and alopecia universalis over a 24-week period, but longer studies are needed to assess long-term safety.

This essay reviews issues related to telogen effluvium, including diagnosis, classification, and management, but it reports no new clinical findings.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

This review discusses telogen effluvium as a common cause of diffuse hair loss and reports no new clinical results, noting diagnostic and treatment challenges.

This study introduces three spectrophotometric techniques for accurately determining finasteride and tadalafil in their combined pharmaceutical form, demonstrating their sustainability, sensitivity, and suitability for quality assurance, alongside a dissolution study following FDA guidelines.

This case report describes a 43-year-old male with alopecia totalis who successfully regrew all his hair after six months of treatment with tofacitinib, with no relapse at one year.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

This review discusses the various triggers and diagnostic challenges in determining the cause of telogen effluvium-related hair loss, without providing new clinical results.

This study found that Tofacitinib effectively improved hair regrowth in patients with Alopecia Areata, with most participants showing a significant change in their Severity of Alopecia Tool scores.

This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.

This study concluded that patients with chronic telogen effluvium had significantly lower levels of serum ferritin and lactoferrin compared to controls, suggesting potential benefits of supplementation.

This study found that individuals with Telogen Effluvium had significantly lower levels of vitamin D compared to healthy individuals, with a particularly negative correlation observed between disease duration and vitamin D levels in affected patients.

In this study, tofacitinib showed significant efficacy in treating alopecia totalis and universalis over a 6-month period, with notable hair regrowth outcomes, while younger age of onset and shorter treatment duration were linked to less effectiveness.

In this study, gelatin-coated transferosomes were developed to deliver tofacitinib specifically to hair follicles, resulting in 80% hair regrowth in alopecia areata patients with recalcitrant lesions after 12 weeks of treatment.

In this case report, a female patient with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvement in symptoms, including hair loss and lesions, after six months of treatment with tofacitinib, with no recurrence or adverse effects over a two-year follow-up.

In this case report, a 7-year-old boy with alopecia totalis experienced significant hair regrowth after adding topical tofacitinib and mometasone to his treatment regimen, suggesting potential benefits of topical Janus kinase inhibitors for pediatric patients with this condition.

This study found that skin exposure to toluene diisocyanate in mice creates immune-recognition reservoirs in the skin's stratum corneum and hair follicles, potentially leading to sensitization and allergic reactions.

In this case report, tofacitinib led to significant improvement in arthritis and partial improvement in alopecia for a female patient with systemic lupus erythematosus, with no observed adverse effects.

This study suggests that thyroid autoimmunity may play a role in telogen effluvium pathogenesis, indicating a need for evaluating thyroid autoantibodies in addition to thyroid function tests in these patients.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.

This review examines chronic telogen effluvium, highlighting its distinctive features and the need for reassurance about its non-progressive nature, but reports no new clinical results.

The authors concluded that capecitabine and high-dose toremifene may be an effective treatment option for patients unable to undergo anthracycline or taxane therapies, based on one woman's cancer management.

This study introduced and validated new spectrophotometric methods to simultaneously determine finasteride and tadalafil in Entadfi™ capsules with high sensitivity and without interference from excipients.